Logo
Search

Rules:

Only words with 2 or more characters are accepted
Max 200 chars total
Space is used to split words, "" can be used to search for a whole string (not indexed search then)
AND, OR and NOT are prefix words, overruling the default operator
+/|/- equals AND, OR and NOT as operators.
All search words are converted to lowercase.

Search for "pharmacokinetic"

Displaying results 1 to 8 out of 8

  2010-2018 81%
  ... Voelk C, Trampisch M, Rowland L, Schultz A , Sabo JP. Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or ... J. Effect of gemfibrozil or rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy ... Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects Thyroid. July ... van Schanke A, Zimmermann H, Rübsamen-Schaeff H. 
  Size: 64 K - Created: 09-11-15 - Modified: 07-05-18 13:42
Path: /Expertise/Published Expertise/2010-2018

  1990 – 1999 79%
  ... J, Halabi A , Kleinbloesem CH, Heinig R, Blume H. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase ... KM, Roots I. No effect of liver impairment on the pharmacokinetics of levetiracetam. Eur J Clin Pharmacol 1999 ; 55:No. ... Kurowski M, Eckl KM. Voglibose has no effect on the
  Size: 61 K - Created: 18-11-12 - Modified: 20-12-17 11:58
Path: /Expertise/Published Expertise/1990 – 1999

  2000 – 2009 77%
  ... Giersbergen PL. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan. J Clin ... H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar ... A, Ortland C. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for ...
  Size: 53 K - Created: 09-11-15 - Modified: 20-12-17 11:58
Path: /Expertise/Published Expertise/2000 – 2009

  Info-Point 76%
  ... - The Largest Phase I/II Clinic for large-scale, long-term and challenging trials Flyer Your First Address in Europe For Renal Impairment Pharmacokinetics Flyer Your Preferred Partner In Europe For Clinical Trials In Hepatic Impaired Patients Flyer Aging Population - A Challenge In Drug ...
  Size: 38 K - Created: 18-11-12 - Modified: 20-12-17 11:58
Path: /Info-Point

  Medical Writing 72%
  ... summaries and overviews of Common Technical Documents (CTD)   Development and therapeutic areas: Phase I Clinical pharmacology studies – pharmacokinetics and pharmacodynamics Biologics and biosimilars
  Size: 31 K - Created: 18-11-12 - Modified: 20-12-17 11:58
Path: /Services/Medical Writing

  Early Phase I to IIa 70%
  ... are freshly prepared by trained CRS chefs or delivered by external catering services. Special dietary needs (especially in connection with pharmacokinetic profile days, food-drug interaction studies and the long-term nutrition of hospitalised subjects) can be easily met without affecting ...
  Size: 32 K - Created: 18-11-12 - Modified: 20-12-17 11:58
Path: /Services/Early Phase I to IIa

  Pharmacodynamic Expertise 67%
  ... flow rate Urinary output Urinary electrolyte and cratinin excretion Renal tubular function (lithium clearance) Osmolality Cystatin C Iohexol Pharmacokinetics in patients under dialysis Respiratory Spirometry (FEV, PEV, PEFT) including reversibility testing Spiroergometry Pulmonary function testing ...
  Size: 34 K - Created: 18-11-12 - Modified: 02-05-18 10:39
Path: /Expertise/Pharmacodynamic Expertise

  1981 – 1989 66%
  ... Texas/USA, November 8-11, 1989 Bickel U, Thomsen T , Fischer JP, Kewitz H. Galanthamine: pharmacokinetics and inhibition of cholinesterases in humans. In: Kewitz H, Thomsen T , Bickel U, (eds): ... 30 – June 1, 1989 , Toronto, Canada. Clin Biochem; 22:411. Thomsen T , Bickel U, Kewitz H. Pharmacokinetic and pharmacodynamic data for galanthamine in the treatment of Alzheimer's disease. Berlin ...
  Size: 41 K - Created: 18-11-12 - Modified: 20-12-17 11:58
Path: /Expertise/Published Expertise/1981 – 1989

FooterEnd